Prevention or treatment agent for cerebral amyloid-beta storage diseases

一种淀粉样蛋白、蓄积病的技术，应用在药物组合、医药配方、神经系统疾病等方向，达到提高生活质量的效果

Inactive Publication Date: 2016-11-09
FUJIFILM RI PHARMA
View PDF3 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

These effects have not been seen previously with NSAIDs (eg, indomethacin) and disease-modifying antirheumatic drugs (eg, sulfasalazine, SASP)

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Prevention or treatment agent for cerebral amyloid-beta storage diseases
  • Prevention or treatment agent for cerebral amyloid-beta storage diseases
  • Prevention or treatment agent for cerebral amyloid-beta storage diseases

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0069] Patient: 79-year-old male

[0070] Family History: His father died in his 50s due to cerebral hemorrhage (type unknown). His brother had CAA (cortical cerebral hemorrhage, symptomatic epilepsy) in his 60s, AZD at 72, and died at 76.

[0071] Anamnesis: Since the age of about 60, a deep white matter lesion (by head MRI, T2 *WI diagnosis), moderate cerebral atrophy and mild memory decline in hypodense regions of the lateral ventricles (diagnosed by head CT), and cerebral cortex including hippocampus, parietal and frontal lobes. However, there are no particular problems in daily life.

[0072] Current medical history: Since about 76 years and 0 months, walking difficulty (decreased walking speed and decreased walking stability) appeared and developed slowly. Long-distance continuous walking of more than 600m and walking when carrying heavy objects (more than 10kg) on ​​the hands or shoulders become difficult. Sometimes a short-striding gait, a forward lunge-like gait, ...

Embodiment 2

[0089]An 81-year-old female, from 3 to 4 years ago, became dislike of social activities and contact with people. Further development of functional impairment, the results of the implementation of MMSE examination, with a score of 14 or less. Moderate atrophy of the cerebral cortex, including the parietal lobe, and the hippocampus, confirmed by head imaging examination, was diagnosed as having "moderate dementia caused by AZD" based on clinical and brain imaging observations. In daily life, I have observed the symptoms of forgetting the content of the conversation after 5 minutes, and repeatedly buying the same item when I go out alone (memory impairment). In addition, although I used to like cooking, I can’t cook anymore, and I can’t adjust the taste. I get lost near my home and cannot go home (spatial cognitive impairment), so it is difficult to go out alone. In addition, since I cannot manage the use of antihypertensive drugs, etc. by myself (cognitive impairment in terms o...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

Provided is a prevention or treatment agent for cerebral amyloid beta storage diseases, that contains a substance capable of suppressing the progression, alleviating the symptoms, and improving cerebral amyloid-beta storage diseases. This prevention or treatment agent for cerebral amyloid beta storage diseases has as an effective component thereof a compound (e.g., Iguratimod) indicated by formula (1) or a salt thereof and, as a result, is capable of preventing or treating cerebral amyloid-beta storage diseases such as Alzheimer-type dementia or cerebral amyloid angiopathy.

Description

technical field [0001] The present invention relates to a method for treating various symptoms of amyloid-β accumulation diseases in the brain such as Alzheimer's dementia (hereinafter also referred to as AZD) and cerebral amyloid angiopathy (hereinafter also referred to as CAA). A preventive or therapeutic drug of a substance that improves action. Background technique [0002] AZD is a disease in which amyloid-β is mainly accumulated in the periphery of nerve cells, which causes nerve damage, resulting in a decrease in brain function mainly including brain atrophy and dementia. In AZD, diffuse brain atrophy including the hippocampus, and cerebral cortex such as the frontal and parietal lobes was observed by imaging examination of the head. Drugs with proven effectiveness for the improvement of dementia already exist. However, such agents do not prevent the development of the disorder. None of these drugs has been able to prevent or improve cognitive decline and completel...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/352A61P9/00A61P25/28A61P43/00
CPCA61K31/352A61P9/00A61P25/00A61P25/28A61P43/00
Inventor 柳本广二
Owner FUJIFILM RI PHARMA
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap